Showing results (11-20 of 65) with videos related to

Sort By:
Pageof 7
Journal for Immunotherapy of Cancer|December 18, 2024
Evaluation of immune checkpoint inhibitor efficacy for solid tumors with <i>CD274</i> (PD-L1 gene) amplification identified by comprehensive genomic profiling: retrospective study based on a nationwide databaseTomohiro Nakayama, Takayuki Takahama, Yasutaka Chiba, et al.
Frontiers in Oncology|September 26, 2025
Case Report: A small cell lung cancer transformed from an <i>EGFR</i>-mutated Adenocarcinoma demonstrated a long-term remission to anti PD-1 antibodyYusuke Kawanaka, Kimio Yonesaka, Junko Tanizaki, et al.
Cancer Diagnosis & Prognosis|March 4, 2026
Development of Second Primary Malignancies in Long-term Survivors of Unresectable Esophageal CancerRyotaro Watanabe, Seiichiro Mitani, Masaki Okura, et al.
Cancer Chemotherapy and Pharmacology|February 2, 2017
Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancerToshio Shimizu, Kimio Yonesaka, Hidetoshi Hayashi, et al.
Clinical Case Reports|May 19, 2016
Spontaneous pneumothorax due to bronchopleural fistula following reirradiation for locoregionally recurrent squamous cell lung cancerTakayo Ota, Tomohiro Suzumura, Takamune Sugiura, et al.
International Journal of Molecular Sciences|November 13, 2025
Zongertinib, a Novel HER2 Tyrosine Kinase Inhibitor, Maintains an Anticancer Activity for Trastuzumab Deruxtecan-Resistant Cancers Harboring HER2-OverexpressionTakashi Kurosaki, Shinichiro Suzuki, Kimio Yonesaka, et al.
Lung Cancer (Amsterdam, Netherlands)|November 12, 2019
Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIsMasayuki Takeda, Kazuko Sakai, Hidetoshi Hayashi, et al.
Thoracic Cancer|August 17, 2019
Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFR-mutated non-small cell lung cancerYoshikane Nonagase, Masayuki Takeda, Koichi Azuma, et al.
Molecular Cancer Therapeutics|August 26, 2017
T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive Non-Small Cell Lung CancerSatomi Watanabe, Takeshi Yoshida, Hisato Kawakami, et al.
Frontiers in Medicine|September 10, 2025
Prognostic impact of gene alterations via homologous recombination DNA repair gene alteration status in pancreatic ductal adenocarcinomaYusuke Kawanaka, Chiaki Inagaki, Masaki Okura, et al.
Pageof 7